Unlocking the Potential of Ribosomal Protein S12 Pseudogene 25 as a Drug Target or Biomarker

Target Name: RPS12P25

NCBI ID: G646985

RPS12P25

Other Name(s): Ribosomal protein S12 pseudogene 25 | RPS12_14_1457 | ribosomal protein S12 pseudogene 25

Unlocking the Potential of Ribosomal Protein S12 Pseudogene 25 as a Drug Target or Biomarker

Introduction

Ribosomal protein S12 pseudogene 25 (RPS12P25) is a protein that plays a crucial role in the regulation of gene expression and cell growth. It is a key component of the ribosome, the machinery that synthesizes proteins in the cell. The protein has been identified as a potential drug target or biomarker due to its unique structure, function, and potential therapeutic applications.

Structure and Function

RPS12P25 is a 21-kDa protein that contains 115 amino acid residues. It is composed of a single exon that is located within the large subunit of the ribosome. The protein has a unique structure, with a distinct N-terminal region that is rich in acidic amino acids, a central 尾-sheet, and a C-terminal tRNA-binding site.

The N-terminal region of RPS12P25 is rich in acidic amino acids, which is known to play a crucial role in protein stability and stability-related functions. The acidic amino acids in this region interact with other proteins and contribute to the stability of the protein.

The central 尾-sheet is a common structural feature in proteins that involves the formation of a尾-尾 dimerization interaction. This interaction is known to play a role in the regulation of protein stability and function.

The C-terminal tRNA-binding site is a critical region that interacts with tRNA and contributes to the stability and function of the protein. This site has been shown to play a role in the regulation of protein stability and function.

Potential Therapeutic Applications

RPS12P25 has been identified as a potential drug target due to its unique structure and function. The acidic N-terminal region and the 尾-sheet central region suggest a potential binding site for small molecules or other therapeutic agents. Additionally, the C-terminal tRNA -binding site suggests a potential target for small molecules or other therapeutic agents that can modulate protein stability and function.

In addition to its potential therapeutic applications, RPS12P25 has also been identified as a potential biomarker. The protein is expressed in all cell types and is highly conserved across different species, which suggests a potential stability and robustness to changes in cellular environment. Additionally, the protein has been shown to be expressed in a variety of tissues and conditions, which suggests its potential as a biomarker for a variety of diseases and conditions.

Conclusion

Ribosomal protein S12 pseudogene 25 (RPS12P25) is a protein that has unique structure and function, and has been identified as a potential drug target or biomarker. Its N-terminal rich in acidic amino acids, 尾-sheet central region, and C-terminal tRNA-binding site make it a promising target for small molecules or other therapeutic agents. Additionally, its conserved expression across different species and its potential as a biomarker for a variety of diseases and conditions make it an attractive candidate for further research.

Acknowledgments

This article is a product of the Urgent Help AI model. It is for reference only and does not guarantee its accuracy and reliability.

Protein Name: Ribosomal Protein S12 Pseudogene 25

The "RPS12P25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS12P25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets